Difference between revisions of "Glucarpidase (Voraxaze)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.<ref name="insert">[ | + | Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as [[Methotrexate (MTX)|methotrexate]] by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.<ref name="insert">[https://www.btgplc.com/media/1213/voraxaze-prescribing-information-march-13-1.pdf Glucarpidase (Voraxaze) package insert]</ref><ref>[[Media:Glucarpidase.pdf|Glucarpidase (Voraxaze) package insert (locally hosted backup)]]</ref><ref>[http://www.btgplc.com/products/specialty-pharmaceuticals/voraxaze Glucarpidase (Voraxaze) manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 7: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *Brief patient counseling information can be found in the [https://www.btgplc.com/media/1213/voraxaze-prescribing-information-march-13-1.pdf Glucarpidase (Voraxaze) package insert<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]</ref> | ||
| − | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 1/17/2012: Initial FDA approval | + | * 1/17/2012: Initial FDA approval "for the treatment of toxic plasma [[Methotrexate (MTX)|methotrexate]] concentrations (greater than 1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function." |
==References== | ==References== | ||
Revision as of 04:26, 27 April 2017
General information
Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the [https://www.btgplc.com/media/1213/voraxaze-prescribing-information-march-13-1.pdf Glucarpidase (Voraxaze) package insert[1]
- Glucarpidase (Voraxaze) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1/17/2012: Initial FDA approval "for the treatment of toxic plasma methotrexate concentrations (greater than 1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function."